Study identifier:I-665
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Effects of elimination of gastro-esophageal reflux on omeprazole on parameters of pre-malignant change and de-differentiation (i.e. cell kinetics, and plasminogen activators), on classical histological criteria and further on the extent of Barrett’s epithelium.
Acid Reflux
N/A
-
-
-
-
-
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|